<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:regn="http://regeneron.com/20200807">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_regn_regeneron.com_20200807 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20200807_20200807 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0000872589 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-08-07to2020-08-07" name="dei:EntityCentralIndexKey">0000872589</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-08-07to2020-08-07" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="regn-20200807.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-08-07to2020-08-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-07</xbrli:startDate>
        <xbrli:endDate>2020-08-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_908_edei--DocumentType_c20200807__20200807_zicqvK9yUmI4"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): August 12, 2020 (<span id="xdx_90D_edei--DocumentPeriodEndDate_c20200807__20200807_zNBKr5DaIq42"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">August 7, 2020</ix:nonNumeric></span>)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityRegistrantName_c20200807__20200807_zSzVhegtCWLk"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" name="dei:EntityRegistrantName">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified
in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Commission File Number 000-19034</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
<td style="text-align: center; width: 34%"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20200807__20200807_zjvUmF7cow2c"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">New York</ix:nonNumeric></span></b> <span style="font-weight: normal">&#160;</span></td>
<td style="width: 33%; text-align: center; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityFileNumber_c20200807__20200807_zFkoLpq6AoIj"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" name="dei:EntityFileNumber">000-19034</ix:nonNumeric></span></b></span></td>
<td style="width: 33%; text-align: center; font-size: 10pt; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20200807__20200807_z7UfrT3bQ5rd"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" name="dei:EntityTaxIdentificationNumber">13-3444607</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: top">
<td style="text-align: center; font-size: 10pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif">(State or other jurisdiction of <br />
incorporation)</span></td>
<td style="text-align: center; font-size: 10pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif">(Commission File Number)</span></td>
<td style="text-align: center; font-size: 10pt; font-weight: bold"><span style="font: normal 10pt Times New Roman, Times, Serif">(I.R.S. Employer <br /> Identification No.)</span></td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20200807__20200807_zX8ukscwz6c5"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" name="dei:EntityAddressAddressLine1">777 Old Saw Mill River Road</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressCityOrTown_c20200807__20200807_znNKH2Pzqspe"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" name="dei:EntityAddressCityOrTown">Tarrytown</ix:nonNumeric></span>,
<span id="xdx_90B_edei--EntityAddressStateOrProvince_c20200807__20200807_zDRwEmq5bhMj"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20200807__20200807_zm6VPyI5Tew1"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" name="dei:EntityAddressPostalZipCode">10591-6707</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: normal">(Address
of principal executive offices, including zip code)</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90A_edei--CityAreaCode_c20200807__20200807_zweBW5mZ7AJg"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" name="dei:CityAreaCode">914</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20200807__20200807_zq8DX6z3fCf5"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" name="dei:LocalPhoneNumber">847-7000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-weight: normal">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90B_edei--WrittenCommunications_c20200807__20200807_zo7LH8vwKzia"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_900_edei--SolicitingMaterial_c20200807__20200807_zIVIGhujtd61"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20200807__20200807_z3dXlbjsFU7c"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_902_edei--PreCommencementIssuerTenderOffer_c20200807__20200807_zkav86VAQtX6"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: black 1pt solid; font-size: 10pt; border-image: none; width: 42%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; width: 20%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; width: 38%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b>Name
    of Each Exchange <br />
on Which Registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20200807__20200807_zcBtwa6d2VFb"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" name="dei:Security12bTitle">Common Stock &#8211; par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_907_edei--TradingSymbol_c20200807__20200807_zoyUjpNOWs34"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" name="dei:TradingSymbol">REGN</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_907_edei--SecurityExchangeName_c20200807__20200807_z9vtfHVFIVJ2"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_90F_edei--EntityEmergingGrowthCompany_c20200807__20200807_zpEnRzQe4jI3"><ix:nonNumeric contextRef="From2020-08-07to2020-08-07" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif; text-transform: none"><b>Item
1</b></span>.01. <span style="text-transform: none">Entry into a Material Definitive Agreement</span>.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><i>1.750% Senior Notes
due 2030 and 2.800% Senior Notes due 2050; Base Indenture and First Supplemental Indenture</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On
August&#160;12, 2020, Regeneron Pharmaceuticals, Inc. (&#8220;<span style="text-decoration: underline">Regeneron</span>&#8221;
or the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) issued and sold $1.250 billion&#160;aggregate
principal amount of the Company&#8217;s 1.750% Senior Notes due 2030 (the &#8220;<span style="text-decoration: underline">2030
Notes</span>&#8221;) and $750 million&#160;aggregate principal amount of the Company&#8217;s 2.800% Senior Notes due 2050
(the &#8220;<span style="text-decoration: underline">2050 Notes</span>&#8221; and, together with the 2030 Notes, the
&#8220;<span style="text-decoration: underline">Notes</span>&#8221;). The Notes were registered pursuant to an automatic
shelf registration statement on Form S-3 under the Securities Act of 1933, as amended (Registration Statement No. 333-228352)
(filed with the Securities and Exchange Commission on November&#160;13, 2018) (the &#8220;<span style="text-decoration: underline">Registration
Statement</span>&#8221;), and were issued pursuant to an Indenture, dated as of August&#160;12, 2020 (the &#8220;<span style="text-decoration: underline">Base
Indenture</span>&#8221;), between the Company and U.S. Bank National Association, as trustee (the &#8220;<span style="text-decoration: underline">Trustee</span>&#8221;),
as supplemented by the First Supplemental Indenture thereto, dated as of August&#160;12, 2020 (the &#8220;<span style="text-decoration: underline">First
Supplemental Indenture</span>&#8221; and, together with the Base Indenture, the &#8220;<span style="text-decoration: underline">Indenture</span>&#8221;),
between the Company and the Trustee. Net proceeds to the Company from the issuance and sale of the Notes were approximately
$1,977 million (after deducting underwriting discounts and the Company&#8217;s estimated offering expenses) and were used in
part to repay in full the Sanofi Repurchase Bridge Facility (as defined in Item 8.01 below) and to pay accrued interest and
related fees and expenses in connection therewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes are senior
unsecured obligations of the Company and rank equal in right of payment with Regeneron&#8217;s other existing and future senior
unsecured obligations that are not, by their terms, expressly subordinated in right of payment to the Notes, and senior in right
of payment to any of Regeneron&#8217;s future subordinated indebtedness. The Notes are effectively subordinated to all of Regeneron&#8217;s
existing and future secured indebtedness and other secured liabilities, if any, to the extent of the value of the assets securing
such indebtedness and liabilities; and are structurally subordinated to all existing and future obligations of Regeneron&#8217;s
subsidiaries. The 2030 Notes will accrue interest at the rate of 1.750% per year and will mature on September 15, 2030. The 2050
Notes will accrue interest at the rate of 2.800% per year and will mature on September 15, 2050. Interest on each series of Notes
will be payable semi-annually in arrears on March 15 and September 15 of each year, commencing on March 15, 2021, until their respective
maturity dates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Notes may be redeemed
at the Company&#8217;s option at any time at 100% of the principal amount plus accrued and unpaid interest to, but not including,
the redemption date and, until a specified period before maturity, a specified make-whole amount. The Notes contain a change-of-control
provision that, under certain circumstances, may require the Company to offer to repurchase the Notes at a price equal to 101%
of the principal amount plus accrued and unpaid interest to, but not including, the date of repurchase.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Indenture also
contains certain limitations on the Company&#8217;s ability to incur liens and enter into sale and leaseback transactions, as well
as customary events of default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing summary
of the Indenture is not complete and is qualified in its entirety by reference to the full and complete text of the Base Indenture,
a copy of which is attached hereto as Exhibit 4.1 and is incorporated by reference herein, and the First Supplemental Indenture,
a copy of which is attached hereto as Exhibit 4.2 and is incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-transform: uppercase; text-indent: -49.5pt"><span style="text-transform: none">Item
2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.5pt; text-transform: uppercase; text-indent: -49.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information set
forth in Item 1.01 above with respect to the Notes and the Indenture is hereby incorporated by reference into this Item 2.03 insofar
as it relates to the creation of a direct financial obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in"><span style="text-transform: none">Item
8</span>.01. <span style="text-transform: none">Other Events</span>.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the offering of the Notes, the Company entered into an underwriting agreement, dated August&#160;7, 2020 (the &#8220;<span style="text-decoration: underline">Underwriting
Agreement</span>&#8221;), among the Company and Goldman Sachs &amp; Co. LLC, BofA Securities, Inc., and J.P. Morgan Securities LLC,
as representatives of the several underwriters named therein (the &#8220;<span style="text-decoration: underline">Underwriters</span>&#8221;), providing for the issuance
and sale by the Company to the Underwriters of the Notes. The Underwriting Agreement contains customary representations and warranties,
conditions to closing, indemnification rights, obligations of the parties, and termination provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing summary
of the Underwriting Agreement is not complete and is qualified in its entirety by reference to the full and complete text of the
Underwriting Agreement, a copy of which is attached hereto as Exhibit 1.1 and is incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 10pt">Following
the closing of the issuance and sale of the Notes, the Company repaid in full the $1.5 billion principal amount of loans outstanding
under the credit agreement by and among the Company, as the borrower, Goldman Sachs Bank USA, as administrative agent, sole bookrunner,
sole lead arranger, and a lender, and the other lenders party thereto from time to time (the &#8220;<span style="text-decoration: underline">Sanofi Repurchase Bridge
Facility</span>&#8221;), as well as accrued interest and related fees and expenses in connection therewith. The proceeds of the loans
under the Sanofi Repurchase Bridge Facility</span> were previously used to fund, in part, the purchase by Regeneron of shares of
Regeneron common stock held by Sanofi and to pay related fees, costs, and expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the opinion
of Skadden, Arps, Slate, Meagher &amp; Flom LLP relating to the legality of the issuance and sale of the Notes is attached hereto
as Exhibit 5.1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in">I<span style="text-transform: none">tem
</span>9.01. <span style="text-transform: none">Financial Statements And Exhibits</span>.</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
<td style="border-bottom: Black 1pt solid; width: 10%"><b>Exhibit No.</b></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; width: 88%"><b>Description</b></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><a href="tm2027319d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">1.1</span></a></td>
    <td>&#160;</td>
<td style="text-align: justify"><a href="tm2027319d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Underwriting Agreement, dated August&#160;7, 2020, by and among the Company, Goldman Sachs &amp; Co. LLC, BofA Securities, Inc., and J.P. Morgan Securities LLC, as representatives of the several underwriters named therein.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><a href="tm2027319d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">4.1</span></a></td>
    <td>&#160;</td>
<td style="text-align: justify"><a href="tm2027319d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Indenture, dated August&#160;12, 2020, between the Company and U.S. Bank National Association.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><a href="tm2027319d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">4.2</span></a></td>
    <td>&#160;</td>
<td style="text-align: justify"><a href="tm2027319d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">First Supplemental Indenture, dated August&#160;12, 2020, between the Company and U.S. Bank National Association.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><a href="tm2027319d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">4.3</span></a></td>
    <td>&#160;</td>
<td style="text-align: justify"><a href="tm2027319d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of 1.750% Senior Note due 2030 (included in Exhibit 4.2).</span></a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><a href="tm2027319d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">4.4</span></a></td>
    <td>&#160;</td>
<td style="text-align: justify"><a href="tm2027319d1_ex4-2.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Form of 2.800% Senior Note due 2050 (included in Exhibit 4.2).</span></a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><a href="tm2027319d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">5.1</span></a></td>
    <td>&#160;</td>
<td style="text-align: justify"><a href="tm2027319d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Opinion of Skadden, Arps, Slate, Meagher &amp; Flom LLP.</span></a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><a href="tm2027319d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">23.1</span></a></td>
    <td>&#160;</td>
<td style="text-align: justify"><a href="tm2027319d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font: 10pt Times New Roman, Times, Serif">Consent of Skadden, Arps, Slate, Meagher &amp; Flom LLP (included in Exhibit 5.1).</span></a></td></tr>
<tr style="vertical-align: top">
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td>&#160;</td>
<td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font: 10pt Times New Roman, Times, Serif"><b>REGENERON PHARMACEUTICALS, INC.</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 44%">&#160;</td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: top">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Date: August&#160;12, 2020</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">By: </span></td>
    <td style="border-bottom: Black 1pt solid">/s/ <span style="font: 10pt Times New Roman, Times, Serif">Joseph J. LaRosa</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Name:</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Joseph J. LaRosa</span></td></tr>
<tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Executive Vice President, General Counsel and Secretary</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk38Ae2bFhWxihQRX2O7SrDNlk38O5K3NLaIy8KyzHwzQnTEkhamRIbjLEthj1Vdao+Q4RkZbY7BkazWMYSb4cU4z9r65v2BCQUGAzPqylMehMZ6Nw6LGOS4J1VPTUAOYzWA6UZEXz0hezYFWm90CdoWsGOq2aDX/GoT9vpJlqpXU3VAdoZsDKorW/kNfan6sKW7fhBfHaRpIqJOM5FYMt3qb83NeapgXmIVulyL/jf6ADFtSWw= -->
